pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Big Pharma · news · pharmadog
← back to Big Pharma
News · Big Pharma
94
stories
16d
Post-Hoc Live: Who wants an AstraZeneca-Bristol Myers megadeal?
endpoints
17d
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
fiercebiotech
17d
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
fiercebiotech
17d
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
biopharma dive
17d
Amgen hit with cybersecurity breach, patient data affected
biospace
17d
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
18d
Biotech leaders call for streamlining of INDs as FDA’s Trialblazer rolls out
biospace
18d
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
20d
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
21d
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
21d
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
biospace
21d
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
21d
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
fiercebiotech
22d
New funding, new jobs: 4 biotechs hiring after series B raises
biospace
22d
GSK pens $110M biological datasets pact with AI biotech Relation
fiercebiotech
22d
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
22d
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
23d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
23d
GSK shares rise as $2.5B cost-cutting plan unveiled
biospace
23d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
23d
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
fiercebiotech
24d
After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration
fiercebiotech
24d
From confidence to capital: Positioning biotech for the next growth cycle
biopharma dive
25d
Denmark’s foundation‑fueled biotech boom redraws the Nordic map
biospace
25d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
25d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
27d
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
biospace
27d
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
biospace
28d
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
28d
From Abu Dhabi to Brazil, every region is vying for the ‘new emerging economy’ of biotech
fiercebiotech
← prev
page 2 of 4
next →
